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Abstract
Background: Urothelial carcinoma (UC) is characterized by frequent gene mutations of which activating mutations in FGFR3
are the most frequent. Several downstream targets of FGFR3 are also mutated in UC, e.g., PIK3CA, AKT1, and RAS. Most
mutation studies of UCs have been focused on single or a few genes at the time or been performed on small sample series.
This has limited the possibility to investigate co-occurrence of mutations.
Methodology/Principal Findings: We performed mutation analyses of 16 genes, FGFR3, PIK3CA, PIK3R1 PTEN, AKT1, KRAS,
HRAS, NRAS, BRAF, ARAF, RAF1, TSC1, TSC2, APC, CTNNB1, and TP53, in 145 cases of UC. We show that FGFR3 and PIK3CA
mutations are positively associated. In addition, we identified PIK3R1 as a target for mutations. We demonstrate a negative
association at borderline significance between FGFR3 and RAS mutations, and show that these mutations are not strictly
mutually exclusive. We show that mutations in BRAF, ARAF, RAF1 rarely occurs in UC. Our data emphasize the possible
importance of APC signaling as 6% of the investigated tumors either showed inactivating APC or activating CTNNB1
mutations. TSC1, as well as TSC2, that constitute the mTOR regulatory tuberous sclerosis complex were found to be mutated
at a combined frequency of 15%.
Conclusions/Significance: Our data demonstrate a significant association between FGFR3 and PIK3CA mutations in UC.
Moreover, the identification of mutations in PIK3R1 further emphasizes the importance of the PI3-kinase pathway in UC. The
presence of TSC2 mutations, in addition to TSC1 mutations, underlines the involvement of mTOR signaling in UC.
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Introduction
Urothelial carcinoma (UC) of the bladder, the most common
type of bladder cancer, is characterized by several gene mutations
of which the most frequent is activating mutations in the FGFR3
receptor protein. FGFR3 mutations show a biased distribution of
UC pathological subtypes in which low grade non-invasive tumors
(Ta) shows the highest frequencies, close to 70%, whereas high
grade and muscle invasive tumors ($T2) show considerably lower
frequencies, in the range of 10 to 15%. On the other hand, TP53
mutations show an opposite pattern with high frequencies in
muscle invasive tumors (,50%) and low in non muscle invasive
tumors (,15%). This biased distribution of FGFR3 and TP53
mutations has led to the hypothesis that UC develops along two
different pathways, a FGFR3 and a TP53 pathway, respectively
[1,2]. Alternative explanations for the frequent TP53 mutations in
muscle invasive tumors have however been put forward [3].
Several genes acting downstream of receptor tyrosine kinases
(RTKs) have also been reported to be mutated in UC, e.g. PIK3CA
[4], members of the RAS family [5], BRAF [6], and AKT1 [7].
Another characteristic of UC is the frequent LOH on chromo-
some 9 and this chromosome is believed to harbor more than one
tumor suppressor gene of importance for UC development. At
least two such loci have been established, CDKN2A and TSC1.
CDKN2A shows homozygous deletions in up to 30% of UC [8]
whereas inactivating sequence mutations is seen to a lesser extent.
TSC1, on the other hand, has been reported to be mutated in 16%
of UC [4]. TSC1 is a negative regulator of the mTOR pathway,
which is important for cell proliferation and frequently found
activated in tumors [9] including UC [10,11]. Notably, TSC1 is
regulated by AKT1 and is therefore a potential downstream target
of the FGFR3 signaling pathway. Additional proteins in this
pathway include PIK3R1, PTEN and TSC2. PIK3R1 is a
negative regulator of PIK3CA while PTEN is a negative regulator
of AKT1. TSC2 forms a complex with TSC1 that functions as a
negative regulator of the mTOR pathway. So far no mutation data
on PIK3R1 or TSC2 in UC is available. Recent reports have also
implicated the APC/CTNNB1 pathway in UC [12,13,14]. In the
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mutational landscape of UC. In a series of 145 tumors we
performed mutation analyses of 16 genes, FGFR3, PIK3CA,
PIK3R1, PTEN, AKT1, KRAS, HRAS, NRAS, BRAF, ARAF, RAF1,
TSC1, TSC2, APC, CTNNB1, and TP53.
Methods
Tumors and isolation of nucleic acids
Urothelial tumors were collected by cold-cup biopsies from the
exophytic part of the bladder tumor from 145 patients undergoing
transurethral resection at the University Hospital of Lund,
Sweden, between 2001 and 2005. For detailed patient information
see Table S1. To increase the statistical power, the 145 series of
samples were extended with 73 samples analyzed for FGFR3,
PIK3CA, TP53, HRAS, KRAS, and NRAS mutations only (Table
S1). Tumor pathology, including transurethral and cystectomy
specimens, were reviewed by one pathologist (GC). Written
informed consent was obtained from all patients and the study
was approved by the Local Ethical Committee of Lund University.
Genomic DNA was extracted using the DNeasy Tissue kit
(Qiagen). Genomic DNA was amplified using the Illustra
GenomiPhi V2 DNA Amplification Kit (GE Healthcare) before
further processing.
Mutation analysis
Coding regions in FGFR3, PIK3CA, PIK3R1, PTEN, AKT1,
KRAS, HRAS, NRAS, BRAF, ARAF, RAF1, TSC1, TSC2, APC,
CTNNB1,a n dTP53 were selected and PCR-amplified using
oligonucleotide primers (Table S2). All reactions were carried out
in 96-well plates in a 40 ul mixture containing PCR buffer,
1.5 mM MgCl2, 0.2 mM DNTP, 0.5 mMe a c ho ft h ef o r w a r d
and reverse primers and 1 U TrueStart Taq polymerase
(Fermentas, Helsingborg, Sweden) or Platinum Taq polymerase
(Invitrogen, Carlsbad, CA). The reactions were heated to 94uC
for 5 min, and subjected to 38–41 amplification cycles, followed
by a final elongation step of 10 min at 72uC. Each cycle consisted
of a denaturation step of 30 seconds at 94uC, an annealing step of
30 seconds, and an elongation step of 1 min at 72uC. The
different annealing temperatures used in the different PCRs, as
well as any deviations from the standard reaction mixture are
listed in Table S2. All PCR-amplifications were carried out in a
MBS Satellite Thermal Cycler (Thermo Scientific, Waltham,
MA). Three ml of each PCR product were run on a precast 2%
agarose gel (E-Gel 96 2% agarose GP, Invitrogen) and the
remaining volume was purified on AcroPrep 96 filter plate
Omega 10K (Pall, Ann Arbor, MI), according to the manufac-
turers protocol. The purified PCR products were then sequenced
using the BigDye terminator v1.1, or 3.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA) on a 31306l Genetic
Analyzer (Applied Biosystems). Sequence traces were analyzed
using the SeqScape v2.5 software (Applied Biosystems), and all
sequence variations were validated by re-sequencing independent
PCR products. A change in the DNA sequence was considered to
be a mutation when it changed the amino acid sequence of the
encoded protein or affected a known splice acceptor or donor
site. Sequence changes reported as single nucleotide polymor-
phisms (SNPs) according to Database of Single Nucleotide
Polymorphisms (dbSNP) at NCBI, were omitted from the
analysis. All gene mutations not previously described were
validated by sequencing of blood samples obtained from the
same patient when available (Table S3). Previously not described
mutations were analyzed using the PolyPhen 2 predictor tool
[15].
Statistical analysis
Chi-2 analyses were used to establish significant differences in
proportions between groups. A hypergeometric test was used to
determine if the observed numbers of double mutations was
significantly different from what is expected from a resample
distribution assuming independence.
Results
We screened 145 UCs for sequence mutations in a total of 16
genes, FGFR3, PIK3CA, PIK3R1, PTEN, AKT1, KRAS, HRAS,
NRAS, BRAF, ARAF, RAF1, TSC1, TSC2, APC, CTNNB1, and
TP53. In Figure 1 the results are summarized and the cases are
grouped according to tumor grade. The same data organized
according to tumor stage is provided as Figure S1. Mutation
frequencies are also summarized in Figure 2, along with possible
interactions between the investigated genes. Detailed information
on all identified mutations is given in Table S3.
For FGFR3 we sequenced exons 7, 10, and 15. Mutations in
these exons correspond to 96% of the FGFR3 mutations seen in
tumors of the urinary tract according to the COSMIC database
(www.sanger.ac.uk/genetics/CGP/cosmic). We detected muta-
tions at 7 different amino acid positions, all previously described.
Mutations were seen in 65% of low grade (G1/G2) and in 22% of
high grade tumors (Table 1), and in 63%, 39%, and 22% of Ta,
T1, and $T2, respectively (Figure S1). As expected, the FGFR3
mutation frequency was significantly higher in low grade tumors
(p,0.0001, Chi2 test,) and in non-muscle invasive (NMI)
compared to muscle invasive (MI) cases, 55% and 22%
respectively, (p,0.0002). These results are in line with previous
investigations [16,17,18] and clearly show that FGFR3 mutations
are associated with low grade low stage tumors and with NMI
tumors in particular.
We next performed mutation analysis of TP53 and a total of 52
TP53 mutations (36%) were detected. As expected, we found a
significant difference in frequency between high grade (51%) and
low grade tumors (19%) (p,0.0001). We then tested for possible
negative or positive associations between TP53 and FGFR3
mutations. To increase the power we included mutation data for
an additional 73 cases increasing the number of cases from 145 to
218 and a negative association was observed (p=0.0085,
hypergeometric test). This association is however lost when G1/
G2 and G3 cases are tested separately, p=0.39 and p=0.43,
respectively.
PIK3CA was screened for mutations in exons 9 and 20 that
contain the hotspot positions in which close to all activating
mutations occur [19]. A total of 37 (17%) mutated cases were
detected in the extended series of tumors (n=218). A significantly
higher proportion of PIK3CA mutations was seen in Ta cases
compared to T1 (p,0.05, Chi-2 test), but not between T1 and
$T2, or between NMI and MI cases. PIK3CA mutations was also
associated with low grade (p,0.01). The data also indicated a
possible association between FGFR3 and PIK3CA mutations, with
23 detected double mutations and 14 expected. To further
investigate this we added data for 92 UCs previously published by
Platt et al. [4], 87 published by Lopez-Knowles et al. [20], and 257
by Kompier et al. [18]. In this combined dataset (n=654) a
significant association between FGFR3 and PIK3CA mutations
could be established (hypergeometric test, p,2610
27,9 5
observed double mutants and 68 expected). We then tested for
possible negative or positive associations between PIK3CA and
TP53 mutations but no significant association was observed
(p=0.066, hypergeometric test, n=218). We also performed
mutation analyses of two modulators of PIK3CA activity, PTEN
Gene Mutations in Bladder Cancer
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18583and PIK3R1. All exons of PTEN were sequenced in the 145
tumors but no mutations were identified. For PIK3R1 we
sequenced exons 12, 14, and 15 and found one case with
mutation.
We next sequenced the exons covering codons 12, 13, and 61 in
HRAS, KRAS, and NRAS and detected a total of six mutations in
HRAS, four in KRAS, and none in NRAS (n=218). The overall
frequency of RAS mutations was 5%, which is somewhat lower
than what has been reported in recent investigations using DNA
sequencing [4,18,21]. We further tested for a possible negative
association between RAS and FGFR3 mutations but only found
borderline statistical support for such an association (p=0.059,
hypergeometric test, n=218).
BRAF has been shown to be activated by point mutations in
several different tumor types [22] with the most frequent
mutations located in exons 11 and 15. BRAF belongs to a gene
family that also includes ARAF and RAF1, which mediates signals
from RAS to downstream targets. As RAF mutations, in analogy
with RAS mutations, may show tumor type specificity, we
sequenced exons 11 and 15 in BRAF and the equivalent exons
in ARAF (exons 10 and 13) and RAF1 (exons 11 and 14). In
addition, RAF1 exon 7 was sequenced since activating mutations
in this exon has been described in the Noonan Syndrome [23].
The equivalent exon was also sequenced in ARAF. No mutations
were however detected in any of the RAF genes.
AKT1 is a major downstream target of PIK3CA and is known
to play a key role in the regulation of cell cycle progression,
survival, and mTOR signaling. AKT1 was recently shown to have
activating mutations in exon 4 in UC [7]. We sequenced the
complete exon 4 of AKT1 in our series of 145 tumors and found 2
tumors with an E17K mutation (1%) (Figure 1), associated with
increased and constitutive kinase activity of AKT1 under
conditions of growth factor withdrawal [7].
We screened all 21 coding exons of TSC1 and detected a total of
17 mutations (13%) including truncating, missense, and splice site
mutations. In two additional tumors a substitution of asparagine to
serine was seen at amino acid position 762. Both changes were
however also detected in blood DNA from the respective patients
and hence were considered to be naturally occurring polymor-
phisms. There was no difference in frequency between low and
high grade tumors and TSC1 mutations were seen in FGFR3,
PIK3CA, and in TP53 mutated cases. TSC1 functions together
with TSC2 as an inhibitor of mTOR by maintaining the mTOR
activator RHEB in an inactive state. We therefore sequenced all
coding exons of TSC2 and found a total of 5 mutations in 145
samples (3%). The possible impacts of these mutations on protein
function were investigated by the PolyPhen software. The software
predicted a damaging effect for all four missense mutations, the
fifth being a 1 bp frame shift deletion. TSC2 mutations were seen
in both high and low grade tumors and none of the TSC2 mutated
cases showed concomitant TSC1 mutations. We also tested for
possible associations between TSC1 mutations, or TSC1 and TSC2
combined, and mutations in FGFR3 or TP53. No such association
was however found (p.0.25 in all comparisons, hypergeometric
test, n=145).
We sequenced exon 16 in APC, known to harbor the majority of
APC mutations [24], and exon 3 of CTNNB1 covering the
phosphorylation sites that control ubiquitination and degradation
of CTNNB1. We detected 6 APC mutations in 145 cases (4%),
with no difference between low and high grade tumors. CTNNB1
mutations were seen in 3 cases (2%). We found APC/CTNNB1
mutations in both FGFR3 and TP53 wild type and mutated cases,
indicating that activation of the APC/CTNNB1 signaling pathway
occur independent of FGFR3 and TP53 mutations. All detected
APC mutations were missense mutations. This is in line with
Kastritis et al. [12], who also noted an underrepresentation of
Figure 1. Distribution of identified mutations. In A) low grade (G1/G2) tumors and in B), high grade (G3) tumors. Red squares indicate
inactivating mutation. Green squares indicate activating mutation. For PIK3CA, dark green squares indicate kinase domain mutations and light green
helical domain mutations. At the right, mutation frequencies are given for each gene in the respective tumor grades.
doi:10.1371/journal.pone.0018583.g001
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colorectal cancer. In fact the difference is highly significant. Our
data combined with the data of Kastritis et al. show a significantly
lower frequency of truncating mutations when compared with
data obtained for colorectal cancer from the COSMIC database
(p,0.0001, Chi-2).
Discussion
The aim of the present investigation was to further establish
mutation frequencies for genes commonly mutated in UC, and to
investigate possible positive or negative associations between
mutations. To accomplish this we sequenced 14 genes, previously
shown to be mutated in UC, in 145 cases. FGFR3, PIK3CA, HRAS,
KRAS, NRAS, and TP53 were sequenced in an additional 73 cases.
In addition, we sequenced PIK3R1 and TSC2 as no mutation data
has been published for these two genes in UC. The observed high
frequencies of FGFR3, TP53, and PIK3CA mutations were as
expected. We detected a positive association between FGFR3 and
PIK3CA activating mutations as reported [18,20], and by combing
our data with previously published data we could confirm that this
association is highly significant. Two of our cases showed double
mutations in PIK3CA; one case with a HD and a KD domain
mutation, and one case with two mutations in the HD domain
(E542K E545K). If these double mutations had occurred in
separate alleles could not be determined as the electropherograms
indicated heterozygous mutations. Irrespectively, the repeated
observations of PIK3CA double mutated tumors and cell lines
[4,18,25,26] indicate an additive effect of multiple PIK3CA
mutations.
PTEN acts as negative modulator of PIK3CA and is mutated in
many tumor types as well as in UC [27,28]. No PTEN mutations
were however detected in the present set of tumors, a finding in
line with previous reports of a low PTEN mutation frequency in
UC (2%, n=88) [29,30]. This does however not exclude PTEN as
an important factor in bladder cancer development since PTEN
frequently shows reduced expression [31] as well as homozygous
deletion in UC [29]. As mentioned, PIK3R1 also acts as a negative
modulator of PIK3CA and has been shown to have tumor
suppressor activity [32]. We found one case with a mutation after
sequencing exons 12, 14, and 15, the most frequently mutated
regions in this gene [33]. These exons cover the major part of the
PIK3R1 iSH2 domain that interacts with PIK3CA. The frequent
down regulation of PTEN expression and the here reported
mutational inactivation of PIK3R1 further emphasized the
importance of PIK3CA activity in UC.
Published data on RAS mutation is highly variable with respect
to frequency, the distribution of codon 12 and 13 vs. codon 61
Figure 2. Schematic representation of relationships and
mutation frequencies among the investigated genes. Arrow-
heads, positive regulation; filled circles, negative regulation; gene
names in green, genes showing activating mutations; gene names in
red, genes showing inactivating mutations; gene names in black, genes
with no detected mutations in the present investigation; gene names in
gray, genes not investigated. TP53 is not included in the graph. The
mutation frequencies (%) given are based on the 145 samples
investigated for each gene.
doi:10.1371/journal.pone.0018583.g002
Table 1. Mutation frequencies.
Ta (%)
(n=54)
T1 (%)
(n=36)
$T2 (%)
(n=54)
G1/G2 (%)
(n=68)
G3 (%)
(n=77)
Total
(n=145) Total (%)
Extended
(n=218)
FGFR3 63.0 38.8 22.2 63.2 22.1 61 42.1 82 (37.6%)
PIK3CA 22.2 16.6 9.3 22.1 11.7 24 16.6 37 (17.0%)
PIK3R1 0 2.8 0 1.5 0 1 0.7
RAS 3.7 11.1 1.9 7.4 2.6 7 4.8 10 (4.6%)
AKT1 0 2.8 1.9 1.5 1.3 2 1.4
TSC1 11.1 16.7 9.3 11.8 11.7 17 11.7
TSC2 1.9 8.3 1.9 5.9 1.3 5 3.4
APC 1.9 0 9.3 2.9 5.2 6 4.1
CTNNB1 1.9 5.6 0 2.9 1.3 3 2.1
TP53 14.8 47.2 51.9 19.1 50.6 52 35.9 73 (33.5%)
doi:10.1371/journal.pone.0018583.t001
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and NRAS mutations [5,34,35,36]. The divergent results may
partly be attributed to differences in methods used and partly to
differences in sample selection. In the present investigation HRAS
mutations dominated over KRAS mutations and HRAS codon 61
mutations were much more frequent than codon 12 mutations,
which is in line with most previous investigations.
It has been suggested that RAS mutations may substitute for
FGFR3 mutations and that RAS and FGFR3 mutations therefore
are mutually exclusive [21]. This hypothesis is however weakened
by the fact that samples with concomitant FGFR3 and RAS
mutations were identified in the present investigation as well as in
the studies by Platt et al. and Kompier et al. [4,18]. These findings
may either be explained by intra-tumor heterogeneity as suggested
by Platt et al., or that the biological consequences of activating
FGFR3 and RAS mutations do not overlap completely and
therefore double mutants may result in an additive but small
selective advantage. Irrespective if these mutations are mutually
exclusive or not, the evidence for a strong negative association
between these two genes is compelling [4,18,21]. BRAF operates
downstream of the RAS proteins and has been shown to be
mutated in several tumor types [22]. We did not detect any
mutations in any of the RAF gene family members. Hence, our
data show that the previously reported low frequency or absence of
BRAF mutations is not substituted for by frequent mutations in
either ARAF or RAF1. Consequently, RAF mutations are not as
central for UC development as FGFR3, PIK3CA, and RAS
mutations.
Few and highly divergent mutation frequencies of APC and
CTNNB1 have been reported for UC [12,13,37,38]. Stoehr et al.
found no APC or CTNNB1 mutations in 99 investigated cases,
which is in stark contrast to Kastritis et al. who found 11 APC
mutations in 70 cases (16%), but no CTNNB1 mutations in 35
investigated cases. Shiina et al., on the other hand, identified a
total of 4 CTNNB1 mutations in 64 UC cases (6%). Our results
showing APC mutations in 4% and CTNNB1 mutations in 2% of
the cases are fully compatible with the combined published data
resulting in overall mutation frequencies of 6.5% for APC and
2.0% for CTNNB1.A sAPC and CTNNB1 mutations were not seen
together the frequency of APC/CTNNB1 pathway alteration was
6% in our data. As Kastritis et al. [12], we found a strong bias
towards missense mutations, in contrast to truncating mutations, in
APC and we could show that the mutation spectrum in UC differs
significantly from the spectrum seen in colorectal cancer.
We detected a total of 17 cases (12%) with TSC1 mutations in
our data, which is close to the previously reported frequency of
16% [4]. TSC1 is an established tumor suppressor gene in UC [4]
that exert most of its regulatory function in a complex with TSC2.
Consequently, we also screened TSC2 for mutations and detected
5 mutations in 145 cases (3%). This is a slightly higher frequency
than what has been reported for other investigated solid tumors;
CNS tumors 0.6%, lung cancers 0.9%, ovarian carcinomas 0.6%
(COSMIC database). TSC2 acts as a dimer together with TSC1
by regulating mTOR through RHEB. The activity of TSC1/2 is,
in turn, regulated by input from several upstream regulators [39]
making the TSC1/2 a hub for upstream signals funneled to
mTOR. The combined frequency of TSC1/TSC2 mutations of
15% indicates that a substantial proportion of UC tumors may
show activation of mTOR through TSC1 or TSC2 mutational
inactivation.
All in all, the present investigation emphasizes FGFR3,
PIK3CA/AKT1, and TSC1/TSC2 as important nodes in
intracellular signaling of transformed urothelial cells. To what
extent FGFR3 activation may be directly linked to mTOR
activation remain to be elucidated; we note that FGFR3 and
PIK3CA mutations show a strongly skewed distribution between
low and high grade tumors whereas TSC1/TSC2 mutations were
seen in both categories at almost equal frequencies. Importantly,
the detected alterations in the APC/CTNNB1 signaling pathway
may also influence mTOR activity since GSK3B, an important
member of the APC/CTNNB1 signaling pathway, is one of many
modulators of TSC1 [40,41]. There is further evidence for a
crosstalk between APC/CTNNB1 and TSC1/TSC2 since wild
type, but not inactive or mutated TSC2, regulates CTNNB1
negatively at the level of the CTNNB1 degradation complex [42].
In conclusion our data underscore the possible importance of
mTOR activity in the development of UC. As mTOR activity is
tractable for drug treatment [43,44], and may be a possible target
for various treatment regimes [43,45,46,47], future investigations
should be directed specifically towards mTOR activity in UC.
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given for each gene in the respective tumor stages.
(TIF)
Table S1 Clinical features and mutation data.
(XLS)
Table S2 Primers and PCR conditions.
(XLS)
Table S3 Mutation details.
(XLS)
Acknowledgments
The authors would like to thank Professor Ellen Zwarthoff for sharing
details on the mutation data by Kompier et al., and for giving us useful
comments.
Author Contributions
Conceived and designed the experiments: MH DL. Performed the
experiments: GS CH DL. Analyzed the data: ML GS CH DL GC MH.
Contributed reagents/materials/analysis tools: SG FL WM. Wrote the
paper: GS MH DL.
References
1. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, et al. (2003)
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell
carcinoma of the bladder. Cancer Res 1;63(23): 8108–12.
2. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ´ ER, et al. (2004)
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of
urothelial cell carcinoma. Cancer Res 15;64(6): 1911–4.
3. Lindgren D, Frigyesi A, Gudjonsson S, Sjo ¨dahl G, Hallden C, et al. (2010)
Combined gene expression and genomic profiling define two intrinsic molecular
subtypes of urothelial carcinoma and gene signatures for molecular grading and
outcome. Cancer Res 1;70(9): 3463–72.
4. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, et al. (2009)
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder
cancer. Clin Cancer Res 1;15(19): 6008–17.
5. Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA (2009)
Activation of RAS family genes in urothelial carcinoma. J Urol 181(5): 2312–
9.
Gene Mutations in Bladder Cancer
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e185836. Boulalas I, Zaravinos A, Delakas D, Spandidos DA (2009) Mutational analysis of
the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers
24(1): 17–21.
7. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, et al. (2010) AKT1
mutations in bladder cancer: identification of a novel oncogenic mutation that
can co-operate with E17K. Oncogene 7;29(1): 150–5.
8. Heidenblad M, Lindgren D, Jonson T, Liedberg F, Veerla S, et al. (2008) Tiling
resolution array CGH and high density expression profiling of urothelial
carcinomas delineate genomic amplicons and candidate target genes specific for
advanced tumors. BMC Med Genomics 31;1: 3.
9. Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction
pathway as a target for cancer therapy. Oncogene 27;19(56): 6680–6.
10. Gust KM, So AI (2009) The role of mTOR in bladder cancer. Cancer Biol Ther
8(24): 2348–50.
11. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, et al. (2010) Mammalian
Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor
Growth in Urothelial Carcinoma. Am J Pathol 176(6): 3062–72.
12. Kastritis E, Murray S, Kyriakou F, Horti M, Tamvakis N, et al. (2009) Somatic
mutations of adenomatous polyposis coli gene and nuclear b-catenin
accumulation have prognostic significance in invasive urothelial carcinomas:
evidence for Wnt pathway implication. Int J Cancer 1;124(1): 103–8.
13. Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, et al. (2002) Beta-
catenin mutations correlate with over expression of C-myc and cyclin D1 Genes
in bladder cancer. J Urol 168(5): 2220–6.
14. Zhu X, Kanai Y, Saito A, Kondo Y, Hirohashi S (2000) Aberrant expression of
beta-catenin and mutation of exon 3 of the beta-catenin gene in renal and
urothelial carcinomas. Pathol Int 50(12): 945–52.
15. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010)
A method and server for predicting damaging missense mutations. Nat Methods
Apr;7(4): 248–9.
16. Herna ´ndez S, Lo ´pez-Knowles E, Lloreta J, Kogevinas M, Amoro ´s A, et al.
(2006) Prospective study of FGFR3 mutations as a prognostic factor in
nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 1;24(22):
3664–71.
17. Van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, et al.
(2003) Molecular grading of urothelial cell carcinoma with fibroblast growth
factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of
clinical outcome. J Clin Oncol 15;21(10): 1912–21.
18. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH,
et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder
Cancer and Their Potential as Biomarkers for Surveillance and Therapy. PLoS
One 3;5(11): e13821.
19. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, et al. (2009) PIK3CA
mutation associates with improved outcome in breast cancer. Clin Cancer Res
15;15(16): 5049–59.
20. Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, et al. (2006)
PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3
Mutations in Superficial Papillary Bladder Tumors. Cancer Res 66(15): 7401–4.
21. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF (2005) FGFR3
and Ras gene mutations are mutually exclusive genetic events in urothelial cell
carcinoma. Oncogene 4;24(33): 5218–25.
22. Edlundh–Rose E, Egyha ´zi S, Omholt K, Ma ˚nsson-Brahme E, Platz A, et al.
(2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical
characteristics: a study based on mutation screening by pyrosequencing.
Melanoma Res 16(6): 471–8.
23. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, et al. (2007)
Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat
Genet 39: 1013–1017.
24. Lagarde A, Rouleau E, Ferrari A, Noguchi T, Qiu J, et al. (2010) Germline APC
mutation spectrum derived from 863 genomic variations identified through a 15-
year medical genetics service to French patients with FAP. J Med Genet 47(10):
721–2.
25. Saal LH, Holm K, Maurer M, Memeo L, Su T, et al. (2005) PIK3CA mutations
correlate with hormone receptors, node metastasis, and ERBB2, and are
mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res
1;65(7): 2554–9.
26. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, et al. (2005) PIK3CA gene is
frequently mutated in breast carcinomas and hepatocellular carcinomas.
Oncogene 17;24(8): 1477–80.
27. Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer.
Annu Rev Pathol 4: 127–50.
28. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, et al. (2009)
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K
activation. Cancer Cell 8;16(6): 463–74.
29. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, et al. (1998) Point
mutation and homozygous deletion of PTEN/MMAC1 in primary bladder
cancers. Oncogene 18;16(24): 3215–8.
30. Aveyard JS, Skilleter A, Habuchi T, Knowles MA (1999) Somatic mutation of
PTEN in bladder carcinoma. Br J Cancer 80(5–6): 904–8.
31. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, et al.
(2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes
Dev 15;23(6): 675–80.
32. Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, et al. (2010)
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor
suppressor properties through negative regulation of growth factor signaling.
Cancer Res 1;70(13): 5305–15.
33. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated
genomic analysis of human glioblastoma multiforme. Science 26;321(5897):
1807–12.
34. Olderøy G, Daehlin L, Ogreid D (1998) Low-frequency mutation of Ha-ras and
Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res
18(4A): 2675–8.
35. Cattan N, Saison-Behmoaras T, Mari B, Mazeau C, Amiel JL, et al. (2000)
Screening of human bladder carcinomas for the presence of Ha-ras codon 12
mutation. Oncol Rep 7(3): 497–500.
36. Przybojewska B, Jagiello A, Jalmuzna P (2000) H-RAS, K-RAS, and N-RAS
gene activation in human bladder cancers. Cancer Genet Cytogenet 121(1):
73–7.
37. Stoehr R, Krieg RC, Knuechel R, Hofstaedter F, Pilarsky C, et al. (2002) No
evidence for involvement of beta-catenin and APC in urothelial carcinomas.
Int J Oncol 20(5): 905–11.
38. Shiina H, Igawa M, Urakami S, Shigeno K, Yoneda T, et al. (2001) Alterations
of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced
murine bladder cancer. Cancer Res 1;61(19): 7101–9.
39. Rosner M, Freilinger A, Hengstschla ¨ger M (2004) Proteins interacting with the
tuberous sclerosis gene products. Amino Acids Oct;27(2): 119–28.
40. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, et al. (2006) TSC2 integrates
Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3
to regulate cell growth. Cell 8;126(5): 955–68.
41. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, et al. (2008) A GSK-3/
TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose
transporter expression. Am J Physiol Cell Physiol 295(3): C836–43.
42. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS (2003) The
tuberin-hamartin complex negatively regulates beta-catenin signaling activity.
J Biol Chem 21;278(8): 5947–51.
43. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, et al. (2010) Beyond rapalog
therapy: preclinical pharmacology and antitumor activity of WYE-125132, an
ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer
Res 15;70(2): 621–31.
44. Garcia JA, Danielpour D (2008) Mammalian target of rapamycin inhibition as a
therapeutic strategy in the management of urologic malignancies. Mol Cancer
Ther 7(6): 1347–54.
45. Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, et al. (2009)
Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of
progressive bladder cancer. Cancer Prev Res 2(12): 1008–14.
46. Svirshchevskaya EV, Mariotti J, Wright MH, Viskova NY, Telford W, et al.
(2008) Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host
immunity. BMC Cancer 21;8: 176.
47. Hou G, Zhang Q, Wang L, Liu M, Wang J, et al. (2010) mTOR inhibitor
rapamycin alone or combined with cisplatin inhibits growth of esophageal
squamous cell carcinoma in nude mice. Cancer Lett 28;290(2): 248–54.
Gene Mutations in Bladder Cancer
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18583